COMMUNIQUÉS West-GlobeNewswire

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands
12/08/2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format [...]
SRx Health Solutions Initiates Restructuring Proceedings under CCAA for its Canadian Subsidiary
12/08/2025
U.S. operations, including Halo subsidiary, will not be affected by CCAA Proceedings; No U.S. bankruptcy filing expected TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) ( [...]
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
12/08/2025
Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, 2025 BEDFORD, Mass [...]
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
12/08/2025
- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026 [...]
Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis
12/08/2025
San Diego, Aug. 12, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis SAN DIEGO – August [...]
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
12/08/2025
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH [...]
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
12/08/2025
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease [...]
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
12/08/2025
Conference call will be held today, Tuesday, August 12 at 9:00 am ET CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable [...]
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
12/08/2025
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ [...]
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
12/08/2025
Reports second quarter 2025 total revenue of $7.3 million , representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. [...]
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
12/08/2025
$20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company’s financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass., Aug. 12, 2025 (GLOBE [...]
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
12/08/2025
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions [...]
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
12/08/2025
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions [...]
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
12/08/2025
KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE [...]
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
12/08/2025
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated with ianalumab also [...]
Phonak unveils Virto R Infinio: the compact rechargeable hearing aid designed for today's active lifestyle
12/08/2025
STÄFA, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Phonak , a global leader in hearing care solutions is excited to introduce the Virto R Infinio, its most compact rechargeable custom in-the-ear (ITE) hearing aid [...]
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
12/08/2025
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support global Sandoz [...]
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
12/08/2025
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024 Cash and cash equivalents of €161.3 million at end of June 2025 Further clinical and regulatory progress 2025 financial outlook [...]

Pages